Pratia LLC, part of Humaneva Group, has acquired a majority stake in P1 Trials, a U.S.-based early‑phase oncology clinical research network, expanding access to investigational cancer therapies across Europe and the United States.
P1 Trials operates community-based oncology practices in Washington, Texas and Indiana, providing the infrastructure and support needed to conduct early‑phase studies where patients receive care. The company standardizes operations to enable community practices to run complex trials to a unified global standard.
The investment creates one of the few global research ecosystems dedicated exclusively to early‑phase oncology, linking North America and Europe to accelerate development of next‑generation cancer treatments. Both organizations describe the partnership as patient-centric and focused on bringing innovative therapies to patients in their communities.
Pratia currently reaches more than 65 million patients across Europe through its integrated research sites; adding P1 Trials extends that reach into the U.S., enhancing both companies’ ability to deliver studies in the world’s largest oncology research market. The deal strengthens Pratia’s presence in the United States and underscores its commitment to closer collaboration with practicing oncologists to speed treatment development.
According to the American Association for Cancer Research, about 18.6 million cancer survivors were living in the U.S. as of January 2025. The World Health Organization estimates there are roughly 3.7 million new cancer cases annually across Europe.
“The partnership with Pratia enables us to deliver a truly homogeneous research experience across continents,” said Julio Peguero, MD, President of P1 Trials. “By unifying our scientific rigor, operational standards and patient care models, we’re building a seamless early‑phase oncology network that operates with the same precision and excellence from community practices in the U.S. to leading research centers across Europe. This alignment accelerates innovation and ensures patients everywhere gain faster access to tomorrow’s therapies.”
“P1’s mission has always been to bridge the gap between research and everyday oncology care, ensuring patients have access to pioneering treatments close to home,” said Ron Carozza, PharmD, CEO of P1 Trials. “With Pratia’s global expertise and resources, we can accelerate this mission and bring the latest cancer science directly to patients in their communities faster.”
About Pratia
Pratia, part of the Humaneva Group, is one of Europe’s largest clinical research site networks, operating more than 100 research sites across multiple therapeutic areas with a strong focus on oncology. Pratia partners with sponsors, CROs and healthcare providers to integrate clinical research into everyday care and expand access to innovative treatments for diverse patient populations. www.pratia.com
About P1 Trials
P1 Trials is a U.S.-based clinical research network specializing in early‑phase oncology studies. By partnering with community oncology practices, P1 Trials brings advanced research opportunities directly to patients to enable faster access to next‑generation cancer therapies close to home. www.p1trials.com
Leave a Reply